Franck E. Nicolini

Mutation status and clinical outcome of 89 imatinib mesylate-resistant chronic myelogenous leukemia patients: a retrospective analysis from the French intergroup of CML (Fi(ϕ)-LMC GROUP)

Franck E. Nicolini, Sélim Corm, Q.H. Le et al. · Leukemia · 2006 · 203 citations

Life Sciences, Genetics, Hematology +15

Granulocyte–macrophage colony-stimulating factor (GM-CSF) to increase efficacy of intensive sequential chemotherapy with etoposide, mitoxantrone and cytarabine (EMA) in previously treated acute myeloid leukemia: a multicenter randomized placebo-controlled trial (EMA91 Trial)

Xavier Thomas, Pierre Fenaux, Hervé Dombret et al. · Leukemia · 1999 · 76 citations

Medicine, Hematology, Oncology +17

First-line imatinib mesylate in patients with newly diagnosed accelerated phase-chronic myeloid leukemia

Delphine Réa, Gabriel Étienne, Franck E. Nicolini et al. · Leukemia · 2012 · 44 citations

Medicine, Hematology, Pharmacotherapy +4

Immune checkpoint inhibitor treatment of a first cancer is associated with a decreased incidence of second primary cancer

Pierre-Étienne Heudel, Sylvie Chabaud, David Pérol et al. · ESMO Open · 2021 · 34 citations · Full text

Medicine, Immunology, Oncology +11

Involvement of the <scp>JAK</scp>‐<scp>STAT</scp> pathway in the molecular landscape of tyrosine kinase fusion‐negative hypereosinophilic syndromes: A nationwide <scp>CEREO</scp> study

Matthieu Groh, Laurène Fenwarth, Mathilde Labro et al. · American Journal of Hematology · 2024 · 12 citations · Full text

Life Sciences, Genetics, Molecular Genetics +12